Markers for COVID-19 disease progression: Comprehensive LC-MS characterization of the metabolome with the Xevo G3 QTof
During this webinar you’ll learn about the recently launched Xevo G3 QTof system and discover how its solving problems that matter.
Professor Clare Mills discusses the use of an LC/MS metabolomics approach to profile serum from COVID-19 inpatients. Here they describe how to identify and characterize prognostic biomarkers to support the development of mass spectrometry rapid clinical screening tools.
Tune in to hear more about how the team are planning to characterize immune disfunction as a consequence of SARS-CoV-2 infection.
Key learning objectives
- Discover how the new Xevo G3 QTof system provides comprehensive characterization of analytes
- Develop an understanding of LC/MS and its use in metabolomic and lipidomic studies
- Delve into the world of omics, identifying statistically relevant markers for disease and the impact on patients
Who should attend?
- Scientists interested in characterizing a range of analytes with LC/MS
- Lab managers who want high-throughput, benchtop QTof technology that helps solve problems in their lab
Presenter: Professor Clare Mills (University of Manchester)
Prof Mills is Professor of molecular allergology at the University of Manchester. Her research is focused on applying molecular science to understand, better diagnose and treat food allergies.
Presenter: Dr. Jayne Kirk (Waters Corporation)
Dr. Kirk is a Product Marketing Manager at Waters with over 18 years’ experience in LC/MS instrumentation, technologies and software. She graduated from York University, UK, with a PhD in Analytical Chemistry and has previously held several scientific roles at Waters, developing applications and supporting customers. Her passion for translating technical information into impactful scientific messaging was the driving force behinds her move to marketing.
Presenter: (Carrie Haslam, SelectScience)
Dr. Carrie Haslam is an Associate Editor at SelectScience, playing a key role in content production and specializing in Materials Science, Alzheimer’s disease and Clinical Diagnostics. Carrie completed a Ph.D. from The University of Plymouth, where she developed graphene-based biosensors for the early diagnosis of Alzheimer’s disease.
